Skip to primary navigation
Skip to main content
Skip to primary navigation
Skip to main content
Toggle Search
Search
Choose which site to search.
Current site
All of UAMS
University of Arkansas for Medical Sciences
Winthrop P. Rockefeller
Cancer Institute
UAMS Health
Jobs
Giving
Toggle Search
Toggle Primary Nav
About
From the Director
Our History
Leadership
Board of Advisors
Health Equity and Workforce Development
About Little Rock
Maps & Directions
Cancer Institute Magazine
News
College of Medicine
Patient Care
Clinical Trials
Research
Research Programs
Membership
Clinical Research
Funding Opportunities
Shared Resources
Training and Education
Get Involved
Donate
Fundraising Events
Volunteer Services & Auxiliary
The Envoys
Contact
University of Arkansas for Medical Sciences
Winthrop P. Rockefeller Cancer Institute
All Clinical Trials
Trials: All Clinical Trials
You are here:
Find a Clinical Trial
All Clinical Trials
A Prospective Observational Study of Patients with Monoclonal Gammopathy (MGUS) and Asymptomatic Mulitple Myeloma
June 20, 2024
Brain REST (RESilience to Cancer Therapy)
June 20, 2024
Detection of Doxorubicin Cardiotoxicity Using Peripheral Blood Transcriptome
June 20, 2024
Gut Microbiome in Acute Leukemia and Allogeneic Stem Cell Transplant Patients
June 20, 2024
NCT01166009 – National Marrow Donor Program Research Database for Hemotopoietic Stem Cell Transplantation and Marrow Toxic Injuries
July 24, 2024
NCT01776905 – (IRB#133965) In vivo real-time detection of circulating melanoma cells
July 24, 2024
NCT03233191 – EA1151 Tomosynthesis Mammographic Imaging Screening Trial (TMIST)NCT03233191 –
June 20, 2024
NCT03609216 – A031701 A Phase II Study of Gemcitabine Plus Cisplatin Chemotherapy in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations
July 24, 2024
NCT03678025 – S1802 “Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
June 20, 2024
NCT03723928 – S1703 Randomized Non-inferiority Trial Comparing Overall Survival of Patients Monitored With Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients With Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer
June 20, 2024
NCT03763370 – Expanded Access Program for belantamab mafodotin in Patients with Relapsed/Refractory Multiple Myeloma who are Refractory to a Proteasome Inhibitor, and an Immunomodulatory Agent, and an Anti-CD38 Antibody
June 20, 2024
NCT03801876 – NRG-GI006 Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer
September 18, 2024
NCT03851445 – LUNGMAP – A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
June 20, 2024
NCT03860883 – S2015 Melanoma Margins Trial (MelMarT): A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigation 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma
June 20, 2024
NCT03930680 – Prevention of Heart Failure induced by Doxorubicin with Early Administration of Dexrazoxane (PHOENIX 1)
July 24, 2024
NCT03933904 – A Phase II, Single-Arm Open-Label Multi-Center Study of Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease
July 8, 2024
NCT03997370 – NRG-GY022 Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin
June 20, 2024
NCT04095364 – NRG GY019 A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
July 24, 2024
NCT04134260 – NRG-GU008 Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer after Radical Prostatectomy (INNOVATE) INtensifying treatment for NOde positive prostate cancer by Varying the hormonal Therapy
July 24, 2024
NCT04137107 – A221805 Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
July 24, 2024
NCT04161885 – A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitidine after allogeneic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (VIALE-T)
June 20, 2024
NCT04333537 – NRG-HN006 Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer
June 20, 2024
NCT04400591 – Expanded Access Protocol (EAP) for Patients Receiving Lisocabtagene Maraleucel that is Nonconforming for Commercial Release
July 24, 2024
NCT04427384 – A Multicenter Observational Study of GammaTile Surgically Targeted Radiation Therapy (STaRT) in Intracranial Brain Neoplasms
June 20, 2024
NCT04457596 – Alliance A011801, The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib
July 24, 2024
NCT04513717 – NRG GU009 – Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT*)
July 24, 2024
NCT04586426 – A Phase 1b/2 Dose Escalation and Expansion Study of the Combination of the Bispecific T Cell Redirection Antibodies Talquetamab and Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma
June 20, 2024
NCT04625647 – S1900E, A Phase II Study of AMG 510 in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)
June 20, 2024
NCT04634552 – A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma
June 20, 2024
NCT04637763 – A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
September 18, 2024
NCT04657068 – A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors
June 20, 2024
NCT04671667 – EA3191 A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab after Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features
June 20, 2024
NCT04742907 – Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of TU-100 as an Adjunct to an Enhanced Recovery after Surgery (ERAS) Protocol in Subjects Undergoing Bowel Resection
July 24, 2024
NCT04771078 – Expanded Access Protocol (EAP) for Subjects Receiving Idecabtagene Vicleucel that is Nonconforming for Commercial Release
June 20, 2024
NCT04794699 – An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) in Adult Participants with Advanced Solid Tumors
July 24, 2024
NCT04799275 – S1918 A Phase II/III Randomized Study of R-MiniCHOP with or Without CC-486 (Oral Azacitidine) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas with MYC AND BCL2 and/or BCL6 Rearrangements
June 20, 2024
NCT04852887 – NRG-BR007: A Phase III Clinical Trial Evaluating De-escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score = 18 Breast Cancer
July 24, 2024
NCT04920474 – Protocol for a Research Sample Repository for Allogeneic Unrelated Hematopoietic Stem Cell Transplantation
June 20, 2024
NCT04930159 – The Social Interventions for Support during Treatment for Endometrial Cancer and Recurrence (SISTER) Study
July 24, 2024
NCT05023486 – NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies
June 20, 2024
NCT05050084 – NRG GU010 “Parallel Phase III Randomized Trials of Genomic Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)”
July 24, 2024
NCT05050162 – NRG-HN009: Randomized Phase II/III Trial of Radiation With Cisplatin at 100 mg/m2 Every Three Weeks Versus Radiation With Weekly Cisplatin at 40 mg/m2 for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
June 20, 2024
NCT05095376 – NRG-BN011 A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients with Methylated MGMT Promoter Glioblastoma
June 20, 2024
NCT05096663 – S1900G, “A Randomized Phase II Study of INC280 (capmatinib) plusOsimertinib with or without Ramucirumab in Participants with EGFR-Mutant, METAmplifiedStage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)”
June 20, 2024
NCT05174169 – NRG-GI008: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-NORTH AMERICA)
July 24, 2024
NCT05197881 – Daily Adaptive External Beam Radiation Therapy in the Treatment of Carcinoma of the Cervix: A Prospective Trial of an Individualized Approach for Intestinal Toxicity Reduction (ARTIA-Cervix)
July 24, 2024
NCT05220098 – A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients with Unresectable Locally Advanced or Metastatic Cancer
July 24, 2024
NCT05252416 – A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors
July 24, 2024
NCT05256225 – NRG-GY026: a Phase ii/iii Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-Oysk (Herceptin Hylecta) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (Phesgo) in Her2 positive, Stage i-iv Endometrial Serous Carcinoma or Carcinosarcoma
June 20, 2024
NCT05257083 – A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in Participants with Newly Diagnosed Multiple Myeloma who are Transplant Eligible
July 24, 2024
NCT05259839 – M22-947: A Dose Escalation and Expansion Study of ABBV-383 in Combination with Anti-Cancer Myeloma Regimens for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma
June 20, 2024
NCT05327686 – NRG-GU012 – Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)
July 24, 2024
NCT05346835 – Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene autoleucel (cilta-cel) Out-of-Specification (OOS) in patients with Multiple Myeloma
June 20, 2024
NCT05371093 – A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma
June 20, 2024
NCT05409066 – A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to R2 in Subjects with Relapsed or Refractory Follicular Lymphoma (EPCORE™ FL-1)
September 18, 2024
NCT05409066 – A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to R2 in Subjects with Relapsed or Refractory Follicular Lymphoma (EPCORE™ FL-1)
October 22, 2024
NCT05411081 – S2200, A Phase II Randomized Trial of Cabozantinib (NSC #761968) with or without Atezolizumab (NSC #783608) in Patients with Advanced Papillary Renal Cell Carcinoma (PAPMET2)
July 24, 2024
NCT05440760 – Using Virtual Reality Technology to Improve Patient Experience and Quality of Care during Brachytherapy
July 24, 2024
NCT05451810 – A Phase 2, Open-Label Trial to Evaluate Safety of Epcoritamab Monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma(Previously Grade 1-3a) when Administered in the Outpatient Setting
June 20, 2024
NCT05455320 – A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination With Daratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 1 Prior Line of Therapy
June 20, 2024
NCT05548296 – A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon OncoSignature® Status
June 20, 2024
NCT05561387 – S2209, A Phase III Randomized Trial For Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail Or In A Subset of “Intermediate Fit” Comparing Upfront Three-Drug Induction Regimens Followed by Double- or Single-Agent Maintenance
June 20, 2024
NCT05578976 – A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP Compared to R-CHOP in Subjects with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (EPCORE DLBCL-2)
June 20, 2024
NCT05611931 – A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients with p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
September 18, 2024
NCT05633602 – S2302, PRAGMATICA – LUNG: “A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) plus Pembrolizumab (MK-3475; NSC 776864) versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer
June 20, 2024
NCT05633615 – S2114: A Randomized Phase II trial of consolidation therapy following CD19 CAR T-cell treatment for Relapsed/Refractory Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma
June 20, 2024
NCT05643638 – A Multicenter, Randomized, Double-blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of CYP-001 in Combination with Corticosteroids vs Corticosteroids Alone for the Treatment of High-Risk Acute Graft Versus Host Disease
July 24, 2024
NCT05675449 – A Phase 1b, Open-Label Study of Elranatamab in Combination with Carfilzomib Plus Dexamethasone and Elranatamab in Combination with PF-07901801 in Participants with Relapsed Refractory Multiple Myeloma
June 20, 2024
NCT05812807 – Alliance A012103, OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
June 20, 2024
NCT05815160 – A Phase 1, Dose-Escalation and Expansion Study to Assess Safety and Preliminary Antitumor Activity of Debio 0123 in Combination with Carboplatin and Etoposide in Adult Participants with Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy
June 20, 2024
NCT05929768 – S2212, Shorter Anthracycline-Free Chemo Immunotherapy Adapted Topathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study
July 24, 2024
NCT05946213 – NRG-GU013, “The Phase III ‘High Five Trial’ Five Fraction Radiation For High-Risk Prostate Cancer”
July 24, 2024
NCT05952934 – A Phase II Clinical Trial of Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence
June 20, 2024
NCT05972720 – An Open-label, Multicenter Phase 2 Study Evaluating the Efficacy and Safety of CRG-022, a CD22-directed Autologous Chimeric Antigen Receptor (CAR) T-cell Therapy in Participants with Relapsed/Refractory Large B-Cell Lymphoma After CD19-Directed CAR T-cell Therapy
June 20, 2024
NCT06031688 – S1900K A Randomized Phase II Study of Tepotinib with or Without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP SUB-STUDY)
June 20, 2024
NCT06044025 – A feasibility Study Evaluating a Role for Maintenance therapy in Patients with Biochemically Progressive Castration Sensitive Prostate Cancer on Intermittent Androgen Deprivation Therapy
June 20, 2024
NCT06072781 – A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator’s Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
September 18, 2024
NCT06143891 – A Randomized, Double-Blind, Multicenter, Phase 3 Study to Evaluate Efficacy and Safety of Belumosudil in Combination With Corticosteroids Versus Placebo in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease (cGVHD)
July 24, 2024
NCT06143891 – A Randomized, Double-Blind, Multicenter, Phase 3 Study to Evaluate Efficacy and Safety of Belumosudil in Combination With Corticosteroids Versus Placebo in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease (cGVHD)
October 22, 2024
NCT06225596 – A Randomized Open-Label Phase 2/3 Study of BT8009 as Monotherapy or in Combination in Participants with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
October 22, 2024
NCT06297226 – A Phase 2, Open-Label, Multicenter Study of BMS-986393, a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)
September 18, 2024
NCT06313502 – High dose ascorbic acid (HDAA) in patients with plasma cell disorders
June 20, 2024
REG001-09 Evaluation Tracking Project: A Prospective Chart Review of Patients Treated with Radiation Therapy
July 24, 2024
UARK 2005-06, Collection and Distribution of Tissue, Blood, Urine and Clinical Data for Research from Patients at University of Arkansas for Medical Sciences
July 24, 2024
